Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Alvotech (ALVO) and Advanz Pharma on Thursday said that the European Commission has granted marketing authorizations in the ...
“As the first biosimilar to Simponi (golimumab) to gain approval in the European market, we are committed to expanding access ...
Johnson & Johnson's Simponi gains FDA approval for treating pediatric ulcerative colitis, expanding options for young patients with this chronic condition. “Ulcerative colitis is a complex, lifelong ...
"Alvotech and Advanz announce EC approval for Gobivaz biosimilar" was originally created and published by Pharmaceutical ...
Under the partnership between Alvotech and Advanz Pharma, Alvotech is responsible for the development and commercial supply of Gobivaz ®, while Advanz Pharma holds the registration and exclusive ...
REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
Icelandic biosimilars company Alvotech and privately-held UK firm Advanz Pharma today announced that the European Commission ...
SIMPONI (Golimumab) 50mg/0.5mL solution for SC inj from Centocor Ortho Biotech The FDA has approved Simponi (golimumab for subcutaneous injection; Janssen Biotech) to induce and maintain clinical ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved a label update for Janssen’s golimumab to include language that treatment alongside ...
Simponi Aria is available as a 50mg/4mL strength solution for IV infusion; it is administered as a 30-minute infusion. The Food and Drug Administration (FDA) has approved Simponi Aria® (golimumab; ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis in patients ...